CN118556078A - 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 - Google Patents

通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 Download PDF

Info

Publication number
CN118556078A
CN118556078A CN202380017428.4A CN202380017428A CN118556078A CN 118556078 A CN118556078 A CN 118556078A CN 202380017428 A CN202380017428 A CN 202380017428A CN 118556078 A CN118556078 A CN 118556078A
Authority
CN
China
Prior art keywords
antibody
subject
ivig
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380017428.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·B·M·布阿托斯
五反田圭介
四宫贤治
A·A·B·索斯特利
A·P·M·苏布雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Original Assignee
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Chugai Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of CN118556078A publication Critical patent/CN118556078A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202380017428.4A 2022-04-04 2023-04-03 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 Pending CN118556078A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166586 2022-04-04
EP22166586.2 2022-04-04
PCT/EP2023/058605 WO2023194271A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
CN118556078A true CN118556078A (zh) 2024-08-27

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380017428.4A Pending CN118556078A (zh) 2022-04-04 2023-04-03 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20230303670A1 (en) * 2020-06-24 2023-09-28 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Also Published As

Publication number Publication date
MX2024009673A (es) 2024-09-11
JP2025510490A (ja) 2025-04-15
AU2023248634A1 (en) 2024-05-16
CA3251879A1 (en) 2023-10-12
US20250236661A1 (en) 2025-07-24
EP4504773A1 (en) 2025-02-12
IL313962A (en) 2024-08-01
TW202346339A (zh) 2023-12-01
KR20240168923A (ko) 2024-12-02
WO2023194271A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
JP2024156984A (ja) 難治性全身型重症筋無力症の処置のための方法
UA124269C2 (uk) Застосування антагоністу il-13 для лікування атопічного дерматиту
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
WO2023144699A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
US20220356261A1 (en) Treatment for sjögren's syndrome
CN118556078A (zh) 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案
CN118974082A (zh) 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案
US20250154232A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
JP7739537B2 (ja) Ｆｖｉｉｉ模倣二重特異性抗体を２ヶ月に１回投与する方法
WO2025096435A1 (en) Treatment of complement-associated renal diseases
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
CN118076640A (zh) 抗-pla2r自身抗体介导的膜性肾病的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination